Ortland, Imke
Mendel Ott, Monique
Kowar, Michael
Sippel, Christoph
Ko, Yon-Dschun
Jacobs, Andreas H.
Jaehde, Ulrich
Funding for this research was provided by:
Herbert-Worch foundation
Rheinische Friedrich-Wilhelms-Universität Bonn
Article History
Received: 30 April 2022
Accepted: 9 August 2022
First Online: 30 August 2022
Declarations
:
: This was a secondary analysis of the medication data from two prospective studies. For both studies, a positive vote of the ethics committee of the Faculty of Medicine of the University of Bonn was granted and all patients signed an informed consent (reference number 011/15 and 302/15). All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: IO, MK declare that they have no competing interests. UJ, AHJ, YDK report grants from the Herbert-Worch foundation during the conduct of the studies. Upon submission of this manuscript, MMO was employed at Mitsubishi Tanabe Pharma GmbH, however this was not the case during her main contribution to this study. CS reports honoraria from Gilhead outside the submitted work.